Overall survival and rate of cumulative incidence (CI) of CML‐related death were significantly correlated with the disease phase at the time of mutation analysis (CP vs AP‐BP) whatever the presence or absence of a BCR‐ABL KD mutation (Figure 2). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.